FWCC and Caris Life Sciences Partner to Create Tumor DNA Database
Doctors at the LSU Health Shreveport Feist-Weiller Cancer Center will now have access to next-generation technology that determines the unique biological characteristics of each individual patient’s cancer tumor and identifies tailored chemotherapy or radiation regimens to attack it. The new capability is the result of emerging technology called tumor profiling. Feist-Weiller will partner with Caris Life Sciences of Irving, TX to offer the breakthrough technology to cancer patients of University Health Shreveport, a clinical partner of the LSU Health Shreveport School of Medicine. The cancer center is the only one in a 250-mile radius to offer the advanced capability.
The region’s first clinical molecular profiling program will use Caris’ industry leading comprehensive tumor profiling service. The next-generation technology, called Caris Molecular Intelligence TM, will enhance the clinical and research expertise of Feist-Weiller Cancer Center. It will expand the center’s personalized medicine approach to care and offer more precise treatment planning for patients.
In recent years, molecular profiling has become a valuable tool for oncologists when making treatment decisions for patients with difficult-to-treat and/or rare and aggressive cancers. Caris Molecular Intelligence correlates the molecular data from a tumor with biomarker/drug associations from the latest clinical and scientific literature on cancer. This information is used to recommend therapies more or less likely to benefit the patient. It will also identify potential clinical trials for the patient. The system uses traditional pathology analysis methods, along with more-recently developed DNA sequencing technologies.
The partnership with Caris includes clinical support, patient and physician education and system integration. It also creates a forum to pursue joint research opportunities.
For more information on the partnership with Caris Life Sciences, click here.